Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer

NCT ID: NCT00050960

Last Updated: 2012-07-13

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

612 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-05-31

Study Completion Date

2005-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study evaluates the use of Targretin capsules (bexarotene) in combination with standard chemotherapy for the treatment of metastatic Non-Small Cell Lung Cancer (NSCLC) in patients who have not yet received chemotherapy for their lung cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study evaluates the use of Targretin capsules (bexarotene) in combination with Carboplatin and Paclitaxel for the treatment of metastatic non-small cell lung cancer in patients who have not yet received chemotherapy for their lung cancer. Every patient receives a platinum-containing chemotherapy every three weeks for at least four chemotherapy cycles (approximately four months). Half of the patients are randomly assigned to receive Targretin capsules once daily in addition to the chemotherapy. The other half is randomized to receive a standard platinum-containing chemotherapy without Targretin capsules.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-small Cell Lung Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

NSCLC Targretin Retinoid Bexarotene

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

bexarotene with carboplatin and paclitaxel

Group Type EXPERIMENTAL

bexarotene with carboplatin and paclitaxel

Intervention Type DRUG

bexarotene capsules (400 mg/m\^2/day) in combination with carboplatin IV (AUC 6) every 3 weeks and paclitaxel IV (200 mg/m\^2) every 3 weeks. Subjects in this group also received an antilipid agent which was selected at the discretion of the investigator.

carboplatin and paclitaxel

Group Type EXPERIMENTAL

carboplatin and paclitaxel

Intervention Type DRUG

carboplatin IV (AUC 6) every 3 weeks and paclitaxel IV (200 mg/m\^2) every 3 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

bexarotene with carboplatin and paclitaxel

bexarotene capsules (400 mg/m\^2/day) in combination with carboplatin IV (AUC 6) every 3 weeks and paclitaxel IV (200 mg/m\^2) every 3 weeks. Subjects in this group also received an antilipid agent which was selected at the discretion of the investigator.

Intervention Type DRUG

carboplatin and paclitaxel

carboplatin IV (AUC 6) every 3 weeks and paclitaxel IV (200 mg/m\^2) every 3 weeks.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients must have:

* Pathologic (histologic or cytologic) confirmation of NSCLC
* Stage IIIB with malignant pleural effusion or Stage IV disease
* At least one measurable or evaluable NSCLC lesion that has not been previously irradiated unless radiation therapy was more than three weeks prior to entry in the study and the lesion has been shown to have progressed subsequent to the radiation therapy
* ECOG performance status 0 or 1
* Adequate organ system function
* Fasting serum triglycerides that are within the age-adjusted normal range (or normalized with appropriate intervention such as antilipid therapy prior to the initiation of Targretin capsule therapy).

Patients must be able to complete at least four cycles of combination chemotherapy (i.e., approximately four months)

Patients must not have had:

* Brain metastasis
* Prior chemotherapy for NSCLC
* Prior platinum-based chemotherapy for any indication
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Eisai Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Eisai, Inc

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mack Mabry, M.D.

Role: STUDY_DIRECTOR

Ligand Pharmaceuticals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Montgomery Cancer Center, L.L.C.

Montgomery, Alabama, United States

Site Status

Arizona Clinical Research Center, Inc.

Tucson, Arizona, United States

Site Status

Bay Area Cancer Research Group, LLC

Concord, California, United States

Site Status

Compassionate Cancer Care Medical Group, Inc.

Fountain Valley, California, United States

Site Status

Pacific Coast Hematology/Oncology Medical Group, Inc.

Fountain Valley, California, United States

Site Status

California Cancer Care, Inc.

Greenbrae, California, United States

Site Status

Coast Hematology and Oncology Associates

Long Beach, California, United States

Site Status

Metropolitan Hematology/Oncology Medical Group

Los Angeles, California, United States

Site Status

Sant P. Chawla, Inc.

Los Angeles, California, United States

Site Status

UCLA Medical Center

Los Angeles, California, United States

Site Status

Sutter Gould Medical Foundation

Modesto, California, United States

Site Status

Medical Oncology Care Associates

Orange, California, United States

Site Status

Southern California Kaiser Permanente Medical Group

San Diego, California, United States

Site Status

Sharp Health Care

San Diego, California, United States

Site Status

UCSF/Mount Zion Comprehensive Cancer Center

San Francisco, California, United States

Site Status

Medical Group of North County, Inc., San Diego Cancer Center

Vista, California, United States

Site Status

Rocky Mountain Cancer Centers - Midtown

Denver, Colorado, United States

Site Status

Eastern Connecticut Hematology & Oncology

Norwich, Connecticut, United States

Site Status

Georgetown University Hospital

Washington D.C., District of Columbia, United States

Site Status

Washington Cancer Institute

Washington D.C., District of Columbia, United States

Site Status

Comprehensive Cancer Care Specialists of Boca Raton

Boca Raton, Florida, United States

Site Status

University of Florida/Jacksonville

Jacksonville, Florida, United States

Site Status

Watson Clinic

Lakeland, Florida, United States

Site Status

Oncology and Radiation Associates

Miami, Florida, United States

Site Status

Florida Cancer Institute

New Port Richey, Florida, United States

Site Status

Florida Oncology Associates

Orange Park, Florida, United States

Site Status

Cancer Centers of Florida, P.A.

Orlando, Florida, United States

Site Status

South Florida Oncology & Hematology Consultants

Plantation, Florida, United States

Site Status

Medical Oncology Associates of Augusta

Augusta, Georgia, United States

Site Status

Georgia Oncology Partners Research & Education Foundation

Marietta, Georgia, United States

Site Status

St. Luke's/Mountain State Tumor Institute (MSTI)

Boise, Idaho, United States

Site Status

Weiss Memorial Hospital

Chicago, Illinois, United States

Site Status

Northwest Oncology and Hematology, SC

Elk Grove Village, Illinois, United States

Site Status

Lutheran General Cancer Care Center

Park Ridge, Illinois, United States

Site Status

Oncology/Hematology Associates of Central Illinois, P.C.

Peoria, Illinois, United States

Site Status

Hematology Oncology Assoc. of Illinois

Skokie, Illinois, United States

Site Status

Central Indiana Cancer Centers

Indianapolis, Indiana, United States

Site Status

Cancer Care Center

New Albany, Indiana, United States

Site Status

Michiana Hematology-Oncology

South Bend, Indiana, United States

Site Status

Kansas City Oncology and Hematology Group, Kansas City Cancer Centers

Overland Park, Kansas, United States

Site Status

Drs. Carroll, Sheth, and Raghavan

Louisville, Kentucky, United States

Site Status

Southwest Oncology Associates

Lafayette, Louisiana, United States

Site Status

APMC

Metairie, Louisiana, United States

Site Status

Louisiana State University Health Sciences Center

New Orleans, Louisiana, United States

Site Status

Tulane University Health Sciences Center

New Orleans, Louisiana, United States

Site Status

Mercy Medical Center

Baltimore, Maryland, United States

Site Status

Chesapeake Oncology-Hematology Associates

Baltimore, Maryland, United States

Site Status

Associates in Oncology/Hematology PC

Rockville, Maryland, United States

Site Status

Berkshire Hematology Oncology, PC

Pittsfield, Massachusetts, United States

Site Status

University of Michigan Medical Center

Ann Arbor, Michigan, United States

Site Status

Providence Cancer Institute

Southfield, Michigan, United States

Site Status

St. Lukes Hospital

Duluth, Minnesota, United States

Site Status

Minnesota Oncology Hematology, P.A.

Minneapolis, Minnesota, United States

Site Status

Missouri Cancer Associates

Columbia, Missouri, United States

Site Status

Hematology Oncology Centers of the Northern Rockies

Billings, Montana, United States

Site Status

Montana Cancer & Infectious Disease Specialists

Missoula, Montana, United States

Site Status

Cancer and Blood Specialists of Nevada

Henderson, Nevada, United States

Site Status

Nevada Cancer Center

Las Vegas, Nevada, United States

Site Status

Dartmouth-Hitchcock Medical Center

Lebanon, New Hampshire, United States

Site Status

Orange Medical Group

East Orange, New Jersey, United States

Site Status

VA New Jersey Health Care System

East Orange, New Jersey, United States

Site Status

Hematology-Oncology Associates of Northern NJ, PA

Morristown, New Jersey, United States

Site Status

Somerset Hematology Oncology Associates

Somerset, New Jersey, United States

Site Status

University of Medicine & Dentistry of NJ, School of Osteopathic Medicine

Stratford, New Jersey, United States

Site Status

Overlook Oncology Center

Summit, New Jersey, United States

Site Status

San Juan Oncology Associates

Farmington, New Mexico, United States

Site Status

New York Oncology Hematology, P.C., Capital District Hematology Oncology Associates

Albany, New York, United States

Site Status

Erie Medical Center

Buffalo, New York, United States

Site Status

Roswell Park Cancer Institute

Buffalo, New York, United States

Site Status

Arena Oncology Associates

Great Neck, New York, United States

Site Status

Cancer Institute of Long Island, Inc.

Great Neck, New York, United States

Site Status

Cancer Research of Long Island, Inc.

Great Neck, New York, United States

Site Status

Broome Oncology, LLC

Johnson City, New York, United States

Site Status

New York Presbyterian Hospital, Weill Medical College of Cornell University

New York, New York, United States

Site Status

Columbia Presbyterian Medical Center

New York, New York, United States

Site Status

VA Medical Center

Northport, New York, United States

Site Status

New York Oncology Hematology, P.C., Riverview Cancer Care Medical Associates

Rexford, New York, United States

Site Status

South Shore Hematology Oncology Associates, PC

Rockville Centre, New York, United States

Site Status

Raleigh Hematology Oncology Clinic

Cary, North Carolina, United States

Site Status

Northwest Carolina Oncology and Hematology, P.A.

Hickory, North Carolina, United States

Site Status

Nashat Y. Gabrail, MD, Inc.

Canton, Ohio, United States

Site Status

University of Cincinnati, Barrett Cancer Center

Cincinnati, Ohio, United States

Site Status

Columbus Community Clinical Oncology Program

Columbus, Ohio, United States

Site Status

Dayton Oncology/Hematology Consultants

Dayton, Ohio, United States

Site Status

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, United States

Site Status

Cancer Care Associates - Mercy Campus

Oklahoma City, Oklahoma, United States

Site Status

Cancer Care Associates

Tulsa, Oklahoma, United States

Site Status

Oncology/Hematology, Kaiser Permanente Northwest

Portland, Oregon, United States

Site Status

Oncology Hematology of Lehigh Valley, PC

Bethlehem, Pennsylvania, United States

Site Status

Medical Oncology Associates of Wyoming Valley, PC

Kingston, Pennsylvania, United States

Site Status

Charleston Hematology Oncology P.A.

Charleston, South Carolina, United States

Site Status

Liberty Hematology/Oncology

Columbia, South Carolina, United States

Site Status

WJB Dorn VA Medical Center

Columbia, South Carolina, United States

Site Status

Cancer Centers of the Carolinas

Seneca, South Carolina, United States

Site Status

Santee Hematology/Oncology

Sumter, South Carolina, United States

Site Status

Thompson Cancer Survival Center

Knoxville, Tennessee, United States

Site Status

Boston Baskin Cancer Group

Memphis, Tennessee, United States

Site Status

Texas Oncology, P.A.

Arlington, Texas, United States

Site Status

South Austin Cancer Center

Austin, Texas, United States

Site Status

Lone Star Oncology Consultants, P.A.

Austin, Texas, United States

Site Status

Cancer Specialists of South Texas, PA

Corpus Christi, Texas, United States

Site Status

Texas Cancer Center at Medical City

Dallas, Texas, United States

Site Status

Texas Oncology, P.A.

Dallas, Texas, United States

Site Status

Texas Oncology, P.A.

Fort Worth, Texas, United States

Site Status

Texas Oncology, P.A.

Garland, Texas, United States

Site Status

University of Texas, MD Anderson Cancer Center

Houston, Texas, United States

Site Status

Allison Cancer Center

Midland, Texas, United States

Site Status

West Texas Cancer Center

Odessa, Texas, United States

Site Status

Hope Oncology

Richardson, Texas, United States

Site Status

Hematology & Oncology Associates of South Texas

San Antonio, Texas, United States

Site Status

Tyler Cancer Center

Tyler, Texas, United States

Site Status

Texoma Cancer Center

Wichita Falls, Texas, United States

Site Status

Utah Cancer Specialists

Salt Lake City, Utah, United States

Site Status

Arlington Fairfax Hematology Oncology

Arlington, Virginia, United States

Site Status

Hematology Oncology Patient Enterprises, Center for Cancer Care

Charlottesville, Virginia, United States

Site Status

Danville Hematology & Oncology, Inc.

Danville, Virginia, United States

Site Status

Virginia Oncology Associates

Norfolk, Virginia, United States

Site Status

Stark MD, PC

Portsmouth, Virginia, United States

Site Status

Virginia Cancer Institute

Richmond, Virginia, United States

Site Status

Yakima Regional Cancer Care Center, Internal Medicine Associates of Yakima, Inc.

Yakima, Washington, United States

Site Status

Morgantown Internal Medicine Group

Morgantown, West Virginia, United States

Site Status

Sozialmedizinisches Zentrum

Vienna, , Austria

Site Status

Kaiser-Franz-Josef-Spital

Vienna, , Austria

Site Status

Allgemeines offentliches Krankenhaus der barmherzigen Schwestern vom Heiligen Kreuz Pneumologie

Wels, , Austria

Site Status

Algoma Regional Cancer Program - Sault Area Hospital

Sault Ste. Marie, Ontario, Canada

Site Status

Humber River Regional Hospital

Weston, Ontario, Canada

Site Status

S.M.B.D. Jewish General Hospital

Montreal, Quebec, Canada

Site Status

Centre Hospitalier du Pays d'Aix

Aix-en-Provence, , France

Site Status

Centre Hospitalier General de la Region Annecienne

Annecy, , France

Site Status

Centre Hospitalier d'Antibes-Juan-Les-Pins

Antibes, , France

Site Status

CHRU Hopital de Bois Guillaume

Bois-Guillaume, , France

Site Status

DOP International

Créteil, , France

Site Status

Hopital de Draguignan

Draguignan, , France

Site Status

Centre Hospitalier General

Gap, , France

Site Status

Hopital du Cluzeau

Limoges, , France

Site Status

CHU Hopital St. Marguerite

Marseille, , France

Site Status

Centre Regional de Lutte contre le Cancer (CRLC), Val d'Aurelle-Paul Lamarque

Montpellier, , France

Site Status

Hopital Saint Antoine

Paris, , France

Site Status

CHU - Hopital Nord

Saint-Etienne, , France

Site Status

Hopital Saint Anne

Toulon Naval, , France

Site Status

Service de Pneumology, Hopital Adulte de Brabois

Vandœuvre-lès-Nancy, , France

Site Status

Centre Hospitalier

Villefranche Sur Soane, , France

Site Status

Dept. of Internal Medicine, St. Nikolaus-Stiftshospital Andernach

Andernach, , Germany

Site Status

Aesklepios-Fachkliniken Muchen-Gauting

Gauting, , Germany

Site Status

Krankenhaus GroBhansdorf, Zentrum fur Pneumologie und Thoraxchirurgie

GroBhansdorf, , Germany

Site Status

Ludwig-Maximilians Universitat Munchen

München, , Germany

Site Status

Charite Universitatsklinikum der Humboldt-Universitat zu Berlin

SchumannstraBe, Berlin, , Germany

Site Status

Hospital Provincial de Castellon

Castellon, , Spain

Site Status

Hospital Clinico San Carlos

Madrid, , Spain

Site Status

Hospital Universitario Doctor Peset

Valencia, , Spain

Site Status

Hospital Universitario La Fe Servicio de Oncologia

Valencia, , Spain

Site Status

Hospital Arnau de Villanova, Servicio de Oncologia

Valencia, , Spain

Site Status

Hospital Clinico Universitario, Servicio Hematologia y Oncologia

Valencia, , Spain

Site Status

Hospital de Sagunto Servicio de Oncologia

Valencia, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Austria Canada France Germany Spain

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

L1069-48

Identifier Type: -

Identifier Source: org_study_id

NCT00036907

Identifier Type: -

Identifier Source: nct_alias